A prospective, randomized, single-blind, parallel-controlled multicenter trial for evaluating the effectiveness of EndoAngel in improving the detection rate of gastric neoplasms in gastroscopy

Conditions

Gastric neoplasms

Dong Z, Wu L, Du H, Tao X, Wang J, Zeng X, Zhu Y, Tan S, Wang J, Deng M, Yang T, Chen C, Wen L, Li Y, Jiang C, Tang C, Wang Y, Zhao Z, Wang Q, Yu H, Chen C, Ai Y, Pan J, Chen F, Guo Q, Mao X, Li J, Pang H, Hao J, Jiao Y, Wang Q, Zhang H, Ye S, Dang T, Yu L, Hu S, Zhou W, Deng Y, Li Y, Chen B, Xiao B, Liu J, Qin J, Zhang T, Bu T, Shi J, Wang Y, Zhang H, Lin J, Jin L, Yu J, Tang B, Tan X, Yu L, Yu H.

2026-03-09

10.1053/j.gastro.2025.12.020

Effectiveness of an intelligent endoscopic assistant device for detecting gastric neoplasms and its application conditions: a multi-center, randomized, controlled trial

Zehua Dong, Lianlian Wu, Hongliu Du, Xiao Tao, Junxiao Wang et al. (13 authors)

The Lancet Regional Health - Western Pacific2025-02-01

10.1016/j.lanwpc.2024.101308

The effectiveness of a computer-aided system in improving the detection rate of gastric neoplasm and early gastric cancer: study protocol for a multi-centre, randomized controlled trial.

Dong Z, Zhu Y, Du H, Wang J, Zeng X, Tao X, Yang T, Wang J, Deng M, Liu J, Wu L, Yu H.

2023-05-115 citations

10.1186/s13063-023-07346-5

Interventions

Experimental group:endoscopy assisted by EndoAngel, an artificial intelligence system

Control group:routine endoscopy without EndoAngel

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Male or female aged >= 18 years; 2. Gastroscopy is required to further clarify the characteristics of digestive tract diseases; 3. Painless gastroscopy patients; 4. Able to read, understand and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. The subjects meet the contraindications for gastroscopy; 2. The anesthesiologist assessed that the subjects were not suitable for painless gastroscopy; 3. Patients with contraindications to biopsy; 4. Known active upper gastrointestinal bleeding or emergency gastroscopy; 5. Pregnant women; 6. History of gastric surgery or known gastric remnant; 7. The investigator believes that the subjects are not suitable for high-risk diseases or other special conditions to participate in the clinical trial.

Design outcomes

Primary

Measure	Time frame
Detection Rate of Gastric Neoplasms;Early gastric cancer detection rate;	—

Secondary

Measure	Time frame
Detection Rate of premalignant gastric lesions;Biopsy rate;Observation Time;Number of blind spots in gastroscopy;	—

Countries

China

Contacts

Public ContactYu Honggang

Renmin Hospital of Wuhan University

yuhonggang1968@163.com+86 13871281899

Outcome results

None listed